Copertina

Utility-Based Dose Optimization Approaches for Multiple-Dose Randomized Trial Designs Accounting for Multiple Endpoints

Fuente: arXiv

Salvato in:

Dettagli Bibliografici
Autori principali:	DAngelo, Gina, Chen, Guannan, Ran, Di
Natura:	Preprint
Pubblicazione:	2025
Soggetti:	Methodology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Utility‐Based Dose Optimization Approaches for Multiple‐Dose Randomized Trial Designs Accounting for Multiple Endpoints
di: Gina D'Angelo, et al.
Pubblicazione: (2025)

CUI-MET: Clinical Utility Index Dose Optimization Approach for Multiple-Dose, Multiple-Outcome Randomized Trial Designs
di: Zhang, Fanni, et al.
Pubblicazione: (2025)

ROMI: A Randomized Two-Stage Basket Trial Design to Optimize Doses for Multiple Indications
di: Wang, Shuqi, et al.
Pubblicazione: (2024)

ROSE: Randomized Optimal Selection Design for Dose Optimization
di: Wang, Shuqi, et al.
Pubblicazione: (2025)

A Utility Score Framework for Dose Optimization Studies with Binary Efficacy-Safety Endpoints: Sample Size Determination and Bias Characterization
di: Gu, Xuemin, et al.
Pubblicazione: (2026)

BOIN Designs for Dose Escalation With Selected Dose Combinations in Oncology Phase I Trials
di: Chen, Yuxuan, et al.
Pubblicazione: (2026)

Bayesian Optimization for Identification of Optimal Biological Dose Combinations in Personalized Dose-Finding Trials
di: Willard, James, et al.
Pubblicazione: (2024)

Dual-criterion Dose Finding Designs Based on Dose-Limiting Toxicity and Tolerability
di: Yang, Yunlong, et al.
Pubblicazione: (2024)

Bayesian Optimization for Personalized Dose-Finding Trials with Combination Therapies
di: Willard, James, et al.
Pubblicazione: (2023)

A Unified Approach to Covariate Adjustment for Survival Endpoints in Randomized Clinical Trials
di: Zhang, Zhiwei, et al.
Pubblicazione: (2025)

An Adaptive Phase II Trial Design for Dose Selection and Addition in Microfilarial Infections
di: Zehetmayer, Sonja, et al.
Pubblicazione: (2026)

Estimands for Early Phase Dose Optimization Trials in Oncology
di: Mukherjee, Ayon, et al.
Pubblicazione: (2025)

Defining Utility as a Measure of Preference Under Uncertainty in Phase I-II Oncology Dose Finding Trials
di: Hall, Andrew, et al.
Pubblicazione: (2025)

On Cluster Randomized Trials with the Desirability of Outcome Ranking (DOOR) Endpoints
di: Shao, Wanying, et al.
Pubblicazione: (2026)

BE-BOIN: A Dose Optimization Design Accommodating Backfill and Late-Onset Toxicity
di: Chen, Kai, et al.
Pubblicazione: (2025)

Improving Power in Randomized Controlled Trials with Time-to-Event Endpoints: A Risk-Free Approach
di: Zhou, Junyi, et al.
Pubblicazione: (2026)

Precision Dose-Finding Design for Phase I Oncology Trials by Integrating Pharmacology Data
di: Lee, Kyong Ju, et al.
Pubblicazione: (2025)

Testing Prioritized Composite Endpoint with Multiple Follow-up Time Examinations
di: Mou, Yunhan, et al.
Pubblicazione: (2025)

Prediction Intervals for Interim Events in Randomized Clinical Trials with Time-to-Event Endpoints
di: Ratti, Edoardo, et al.
Pubblicazione: (2026)

Incorporating Participants' Welfare into Sequential Multiple Assignment Randomized Trials
di: Wang, Xinru, et al.
Pubblicazione: (2022)

Multiple Randomization Designs: Estimation and Inference with Interference
di: Masoero, Lorenzo, et al.
Pubblicazione: (2024)

Interim Analysis in Sequential Multiple Assignment Randomized Trials for Survival Outcomes
di: Wang, Zi, et al.
Pubblicazione: (2025)

Cost Effectiveness Analyses for Sequential Multiple Assignment Randomized Trials
di: Montoya, Lina M., et al.
Pubblicazione: (2025)

Study Duration Prediction for Clinical Trials with Time-to-Event Endpoints Using Mixture Distributions Accounting for Heterogeneous Population
di: Zhang, Hong, et al.
Pubblicazione: (2023)

Graph Based, Adaptive, Multi Arm, Multiple Endpoint, Two Stage Design
di: Mehta, Cyrus, et al.
Pubblicazione: (2025)

Personalized Two-sided Dose Interval
di: Park, Chan, et al.
Pubblicazione: (2023)

Bridging the Gap Between Design and Analysis: Randomization Inference and Sensitivity Analysis for Matched Observational Studies with Treatment Doses
di: Zhang, Jeffrey, et al.
Pubblicazione: (2024)

A Seamless Phase II/III Design with Dose Optimization for Oncology Drug Development
di: Li, Yuhan, et al.
Pubblicazione: (2024)

Two-dose vs. Three-Dose Optimization Under Sample Size Constraint
di: Sun, Linda, et al.
Pubblicazione: (2026)

A Likelihood Perspective on Dose-Finding Study Designs in Oncology
di: Zhang, Zhiwei
Pubblicazione: (2023)

BOP2-TE: Bayesian Optimal Phase 2 Design for Jointly Monitoring Efficacy and Toxicity with Application to Dose Optimization
di: Chen, Kai, et al.
Pubblicazione: (2024)

Accounting for Multiple Covariates in Non-Stationary Geostatistical Modelling
di: Johnson, Olatunji, et al.
Pubblicazione: (2024)

Estimation and Inference for Win Measures with Multiple Ordinal Endpoints Subject to Missingness
di: Liu, Yi, et al.
Pubblicazione: (2026)

Multiple Outlier Detection in Samples with Exponential & Pareto Tails: Redeeming the Inward Approach & Detecting Dragon Kings
di: Sornette, Didier, et al.
Pubblicazione: (2015)

A Generalized Logrank-type Test for Comparison of Treatment Regimes in Sequential Multiple Assignment Randomized Trials
di: Tsiatis, Anastasios A., et al.
Pubblicazione: (2024)

LORDs: Locally Optimal Restricted Designs for Phase I/II Dose-Finding Studies
di: Sverdlov, Oleksandr, et al.
Pubblicazione: (2025)

Adaptive Randomization Methods for Sequential Multiple Assignment Randomized Trials (SMARTs) via Thompson Sampling
di: Norwood, Peter, et al.
Pubblicazione: (2024)

Collaborative Indirect Treatment Comparisons with Multiple Distributed Single-arm Trials
di: Zhu, Yuru, et al.
Pubblicazione: (2025)

Statistical Operating Characteristics of Current Early Phase Dose Finding Designs with Toxicity and Efficacy in Oncology
di: Sun, Hao, et al.
Pubblicazione: (2024)

Bias in Meta-Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials
di: Long, James P., et al.
Pubblicazione: (2025)